Research Topics
| Bernard RavinaSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
Mov Disord 22:1061-8. 2007..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
The course of depressive symptoms in early Parkinson's diseaseBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA
Mov Disord 24:1306-11. 2009..83-0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course...- The impact of depressive symptoms in early Parkinson diseaseB Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Neurology 69:342-7. 2007..No previous study has systematically examined the impact of depressive symptoms in early, untreated PD... - Long term understanding of study information in research participants with Parkinson's diseaseBernard Ravina
University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
Parkinsonism Relat Disord 16:60-3. 2010..Little is known about research participants' understanding of consent information over the course of a clinical study and the relationship of this information with participant behavior... 
A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...- Local institutional review board (IRB) review of a multicenter trial: local costs without local contextBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Ann Neurol 67:258-60. 2010..This may be an opportune time for the National Institute of Neurological Disorders and Stroke (NINDS) to adopt a central review model... - The relationship between CAG repeat length and clinical progression in Huntington's diseaseBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 23:1223-7. 2008..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials... - A randomized, placebo-controlled trial of latrepirdine in Huntington diseaseKarl Kieburtz
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
Arch Neurol 67:154-60. 2010..To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms... - Impact of belief in neuroprotection on therapeutic intervention in Parkinson's diseaseRodger J Elble
Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
Mov Disord 25:1082-6. 2010..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment... - Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participantsSean R Regner
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Child Neurol 27:1152-8. 2012..However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached... - A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)Radu Constantinescu
Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
J Clin Pharmacol 47:1580-6. 2007 - The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's diseaseDavid J Gill
Department of Neurology, University of Rochester, Rochester, NY, USA
Mov Disord 23:1043-6. 2008..81. The correlation coefficient between the MoCA and a neuropsychologic battery was 0.72. The MoCA is reliable and valid in the PD population and warrants further study as a screening tool for cognitive dysfunction... - Why hasn't neuroprotection worked in Parkinson's disease?Karl Kieburtz
University of Rochester Medical Center, Rochester, NY, USA
Nat Clin Pract Neurol 3:240-1. 2007 - Mortality in Friedreich ataxiaAmy Y Tsou
Department of Neurology, University of Pennsylvania Medical School, USA
J Neurol Sci 307:46-9. 2011..Although cardiac dysfunction is widely accepted as the most common cause of mortality in Friedreich ataxia (FRDA), no studies have evaluated this since the advent of specific clinical and genetic diagnostic criteria... - Neuroprotection in Parkinson's disease: myth or reality?Tiffini Voss
Department of Neurology, University of Rochester School of Medicine and Dentistry, Movement and Inherited Neurological Disorders Unit, Rochester, NY 14620, USA
Curr Neurol Neurosci Rep 8:304-9. 2008..It is hoped that ongoing work in this field will lead to treatments that delay the progression of PD... - Neuroprotection in Parkinson's disease: an elusive goalKevin M Biglan
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
Semin Neurol 27:106-12. 2007..Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects... - Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosisTiffini Voss
University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA, USA
Parkinsonism Relat Disord 19:295-9. 2013..Parkinson's disease psychosis is a frequent and serious complication of advanced disease, but few disease-specific outcome measures exist... - Maternal inheritance and mitochondrial DNA variants in familial Parkinson's diseaseDavid K Simon
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
BMC Med Genet 11:53. 2010..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD... - Preference-based quality-of-life in patients with Parkinson's diseaseAndrew Siderowf
Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 59:103-8. 2002..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups... - Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work GroupLaura Marsh
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Mov Disord 21:148-58. 2006..The proposed diagnostic criteria are provisional and intended to be defined further and validated but provide a common starting point for clinical research in PD-associated depression... - Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safetyTanya Simuni
Parkinson's Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, USA
J Neurosurg 96:666-72. 2002..Serious adverse events were common in this cohort; however, only two patients suffered permanent sequelae... - From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsJill Heemskerk
Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
Nat Neurosci 5:1027-9. 2002 - Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutationStephen Hague
Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
Ann Neurol 54:271-4. 2003..This subject was diagnosed with probable PD at age 24 years with asymmetric onset and an excellent response to levodopa therapy. Our observations suggest that sequence alterations in DJ-1 are a rare cause of early-onset PD... - Exercise-induced dystonia as a preceding symptom of familial Parkinson's diseaseMichiko K Bruno
Parkinson s Unit, Division of Neurogenetics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
Mov Disord 19:228-30. 2004..Further genotype-phenotype studies in this and similar families may give clues to pre-symptomatic symptoms in PD and may reflect a particular phenotype of interest for genetics studies in the future... - A responsive outcome for Parkinson's disease neuroprotection futility studiesJordan J Elm
Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC 29425, USA
Ann Neurol 57:197-203. 2005.... - Widespread decrease of nicotinic acetylcholine receptors in Parkinson's diseaseMasahiro Fujita
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 1, Room B3 10, I Center Drive, MSC 0135, Bethesda, MD, USA
Ann Neurol 59:174-7. 2006..Nicotinic acetylcholine receptors have close interactions with the dopaminergic system and play critical roles in cognitive function. The purpose of this study was to compare these receptors between living PD patients and healthy subjects... - Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trialsPaulo Guimaraes
Dept of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St Suite 303, Charleston, SC 29425, USA
Clin Trials 2:509-18. 2005..Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again... - Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's diseaseMary E Putt
Department of Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 621 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
Control Clin Trials 23:111-26. 2002..4 months, respectively, a substantial saving over either parallel group design. The cost of allowing for carryover in the sample size calculation is about 1.2 months of study time...
Research Grants
- Creatine Safety and Efficacy in HD: Coordination and Statistical CenterBernard Ravina; Fiscal Year: 2007..This will allow NCCAM to distribute authoritative information to the public about the safety of creatine. ..